Inhibikase Therapeutics Stock (NASDAQ: IKT) stock price, news, charts, stock research, profile.
Open | $1.17 |
Close | $1.20 |
Volume / Avg. | 41.41K / 24.83K |
Day Range | $1.17 - $1.22 |
52 Wk Range | 0.79 - 3.82 |
Market Cap | $8.95M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 40 |
Short Interest | 0.66% |
Days to Cover | 1.51 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Inhibikase Therapeutics (NASDAQ:IKT) through any online brokerage.
Other companies in Inhibikase Therapeutics’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Alzamend Neuro (NASDAQ:ALZN), Addex Therapeutics (NASDAQ:ADXN), Coeptis Therapeutics (NASDAQ:COEP) and Can Fite Biofarma (AMEX:CANF).
Inhibikase Therapeutics has a consensus price target of $15.00.
The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $1.199 last updated September 20, 2024 at 4:11 PM EDT.
There are no upcoming dividends for Inhibikase Therapeutics.
Inhibikase Therapeutics’s Q3 earnings are confirmed for Tuesday, November 12, 2024.
There is no upcoming split for Inhibikase Therapeutics.
Inhibikase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.